Please login to the form below

Not currently logged in
Email:
Password:

Portola

This page shows the latest Portola news and features for those working in and with pharma, biotech and healthcare.

CHMP turns down BMS’ Opdivo/Yervoy for kidney cancer

CHMP turns down BMS’ Opdivo/Yervoy for kidney cancer

CHMP turns down BMS’ Opdivo/Yervoy for kidney cancer. The committee also turned down Amgen’s Blincyto, Portola’s Dexxience and Radius International’s Eladynos. ... It also turned down two previously-rejected medicines – Portola’s factor Xa

Latest news

  • CHMP backs first-line use for AZ’s Tagrisso in lung cancer CHMP backs first-line use for AZ’s Tagrisso in lung cancer

    The three drugs in question are Portola’s anticagulant Dexxience (betrixaban), Radius’osteoporosis candidate Eladynos (abaloparatide) and AB Science’s Alsitek (masitinib), filed for neurodegenerative disease amyotrophic lateral sclerosis (ALS).

  • ViiV’s two-drug HIV combo backed by CHMP ViiV’s two-drug HIV combo backed by CHMP

    There was bad news for three other companies, with the CHMP issuing negative opinions for Portola’s Dexxience (betrixaban) for the prevention of venous thromboembolism, Radius International’s osteoporosis candidate Eladynos

  • Bad news for Portola as CHMP considers Factor Xa drugs Bad news for Portola as CHMP considers Factor Xa drugs

    Bad news for Portola as CHMP considers Factor Xa drugs. The committee are ‘unlikely’to adopt a positive opinion for betrixaban. ... Portola Pharmaceuticals’efforts to secure approval for its novel oral anticoagulant (NOAC) and reversal agent in

  • Portola rejection hands advantage to Boehringer's Pradaxa Portola rejection hands advantage to Boehringer's Pradaxa

    Portola rejection hands advantage to Boehringer's Pradaxa. FDA’ s ruling on reversal agent for NOACs unexpected. ... The agency said that it also needs more time to complete its review of certain clinical amendments to Portola's post-marketing

  • Boehringer’s Praxbind granted accelerated approved by FDA Boehringer’s Praxbind granted accelerated approved by FDA

    However, competition is also coming from rivals such as Portola Pharmaceuticals, which is currently undertaking phase III trials of andexanet alfa, which has shown to reverse the effect of other

More from news
Approximately 4 fully matching, plus 11 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2017 Deal Watch February 2017

    Licence, collaboration. 237.5. Portola Pharmaceuticals/ HealthCare Royalty Partners. AndexXa (andexanet alfa) - Factor Xa inhibitor antidote (phase IIIb/IV).

  • Deal Watch February 2016 Deal Watch February 2016

    merger. 106. † Portola Pharmaceuticals/ BMS| Pfizer. andexanet alfa as an antidote for apixaban and other Factor Xa inhibitors (pre-reg).

  • Modern anticoagulants threaten status quo Modern anticoagulants threaten status quo

    Betrixaban. Betrixaban (Portola Pharmaceuticals) is a long-acting oral factor Xa inhibitor that entered phase III trial development for VTE prevention in medically ill patients in March 2012. ... Portola is also developing PRT 064445, which is an

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

  • Sanifit appoints Alexander Gold chief medical officer Sanifit appoints Alexander Gold chief medical officer

    He joins the Palma-headquartered company from Portola Pharmaceuticals, where he served as a senior vice president and head of clinical development. ... Prior to his time at Portola, Dr Gold was head of clinical development at Reata Pharmaceuticals and

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Pegasus

Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...

Latest intelligence

Marketing to healthcare professionals – what’s the key ingredient missing from most campaigns?
What do you think is the difference between a campaign developed to win a share-of-mind with consumers and a campaign designed to gain the attention of healthcare professionals?...
What everyone forgets about good organisational change in pharma
Natasha Cowan speaks to Daphne Chung, Head of Organisational Transformation, to learn how she ensures smooth organisational change that takes all stakeholders into account....
Live from Singapore: Oncology in APAC - Evaluating the opportunity for novel therapies
Live webinar: Tuesday 11th December 2018,16:00 SGT / 17:00 JST...

Infographics